Invesco Confirms Strong Q1 2026 Results with 34% Net Income Growth, $21.8B Inflows, and Increased Dividend
IVZ sits 91% above its 52-week low of $14.04.
Summary
Invesco Ltd. reported strong Q1 2026 financial results, confirming a 34.6% increase in net income and 18% growth in average AUM, alongside an increased common dividend and share repurchases.
Key Events · Earnings and Guidance · IVZ
-
Strong Q1 2026 Financial Performance
Net income attributable to Invesco Ltd. increased by 34.6% to $230.4 million for the three months ended March 31, 2026, compared to $171.1 million in the prior year period. Diluted EPS rose by 34.2% to $0.51.
-
Significant Asset Growth and Inflows
Average Assets Under Management (AUM) grew by 18% to $2.2 trillion for Q1 2026, driven by $21.8 billion in net long-term inflows, primarily from ETFs and Index, China JV, Fundamental Fixed Income, and Multi-Asset/Other.
-
Enhanced Shareholder Returns
The company increased its quarterly common dividend to $0.215 per share and repurchased 1.6 million common shares for $40.0 million in the open market during the quarter.
-
Proactive Debt Management
Invesco redeemed $500.0 million of senior notes that matured on January 15, 2026, demonstrating effective balance sheet management, although total debt increased slightly due to revolving credit agreement borrowings.
Analysis · IVZ · Finance
This 10-Q filing provides the full, detailed financial statements and management's discussion for Q1 2026, confirming the strong preliminary results announced in the 8-K on April 28, 2026. The report highlights significant growth in net income and diluted EPS, driven by robust net long-term inflows and overall AUM expansion. The company's continued commitment to shareholder returns through an increased common dividend and ongoing share repurchases, alongside proactive debt management, underscores a healthy financial position. Investors should view this as a confirmation of positive operational momentum and solid capital management, providing a comprehensive view of the company's financial health.
At the time of this filing, IVZ was trading at $26.77 on NYSE in the Finance sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $14.04 to $29.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.